These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19584159)

  • 1. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.
    Zhang C; Yan Z; Painter CL; Zhang Q; Chen E; Arango ME; Kuszpit K; Zasadny K; Hallin M; Hallin J; Wong A; Buckman D; Sun G; Qiu M; Anderes K; Christensen JG
    Clin Cancer Res; 2009 Jul; 15(14):4630-40. PubMed ID: 19584159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
    Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
    Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.
    Iacobucci I; Di Rorà AG; Falzacappa MV; Agostinelli C; Derenzini E; Ferrari A; Papayannidis C; Lonetti A; Righi S; Imbrogno E; Pomella S; Venturi C; Guadagnuolo V; Cattina F; Ottaviani E; Abbenante MC; Vitale A; Elia L; Russo D; Zinzani PL; Pileri S; Pelicci PG; Martinelli G
    J Hematol Oncol; 2015 Nov; 8():125. PubMed ID: 26542114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.
    Blasina A; Hallin J; Chen E; Arango ME; Kraynov E; Register J; Grant S; Ninkovic S; Chen P; Nichols T; O'Connor P; Anderes K
    Mol Cancer Ther; 2008 Aug; 7(8):2394-404. PubMed ID: 18723486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
    Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
    BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel.
    Gril B; Vidal M; Assayag F; Poupon MF; Liu WQ; Garbay C
    Int J Cancer; 2007 Jul; 121(2):407-15. PubMed ID: 17372910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint kinase 1-mediated phosphorylation of Cdc25C and bad proteins are involved in antitumor effects of loratadine-induced G2/M phase cell-cycle arrest and apoptosis.
    Chen JS; Lin SY; Tso WL; Yeh GC; Lee WS; Tseng H; Chen LC; Ho YS
    Mol Carcinog; 2006 Jul; 45(7):461-78. PubMed ID: 16649252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
    Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
    Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells.
    Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D
    Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
    Manfredi MG; Ecsedy JA; Chakravarty A; Silverman L; Zhang M; Hoar KM; Stroud SG; Chen W; Shinde V; Huck JJ; Wysong DR; Janowick DA; Hyer ML; Leroy PJ; Gershman RE; Silva MD; Germanos MS; Bolen JB; Claiborne CF; Sells TB
    Clin Cancer Res; 2011 Dec; 17(24):7614-24. PubMed ID: 22016509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
    Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
    Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHK1 kinase activity assay.
    Wang HY; Wang Y
    Methods Mol Biol; 2012; 920():603-12. PubMed ID: 22941630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
    Tse AN; Rendahl KG; Sheikh T; Cheema H; Aardalen K; Embry M; Ma S; Moler EJ; Ni ZJ; Lopes de Menezes DE; Hibner B; Gesner TG; Schwartz GK
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):591-602. PubMed ID: 17255282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genistein induces G2/M cell cycle arrest and apoptosis of human ovarian cancer cells via activation of DNA damage checkpoint pathways.
    Ouyang G; Yao L; Ruan K; Song G; Mao Y; Bao S
    Cell Biol Int; 2009 Dec; 33(12):1237-44. PubMed ID: 19732843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.
    Sarmento LM; Póvoa V; Nascimento R; Real G; Antunes I; Martins LR; Moita C; Alves PM; Abecasis M; Moita LF; Parkhouse RM; Meijerink JP; Barata JT
    Oncogene; 2015 Jun; 34(23):2978-90. PubMed ID: 25132270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells.
    Tyagi A; Singh RP; Agarwal C; Siriwardana S; Sclafani RA; Agarwal R
    Carcinogenesis; 2005 Nov; 26(11):1978-87. PubMed ID: 15975956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xanthatin triggers Chk1-mediated DNA damage response and destabilizes Cdc25C via lysosomal degradation in lung cancer cells.
    Tao L; Cao Y; Wei Z; Jia Q; Yu S; Zhong J; Wang A; Woodgett JR; Lu Y
    Toxicol Appl Pharmacol; 2017 Dec; 337():85-94. PubMed ID: 29074359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chk1-Mad2 interaction: a crosslink between the DNA damage checkpoint and the mitotic spindle checkpoint.
    Chilà R; Celenza C; Lupi M; Damia G; Carrassa L
    Cell Cycle; 2013 Apr; 12(7):1083-90. PubMed ID: 23454898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.